Request availability and a quotation for your required quantity and destination.
| Product | Semaglutide 1 mg - Wegovy Pen |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Active ingredient: Semaglutide
Strength: 1 mg
Dosage form: Subcutaneous injection pen
Medicine class: GLP-1 receptor agonist
Prescription status: Prescription medicine
Wegovy 1 mg contains semaglutide, a GLP-1 receptor agonist used as part of medically supervised chronic weight management in eligible patients alongside reduced-calorie nutrition and increased physical activity. This is a dose-escalation strength used as treatment is gradually increased. The correct strength and timing of dose escalation must be determined by the prescriber.
Wegovy is used for long-term weight management in eligible people with obesity, or overweight with qualifying weight-related health conditions, according to the approved indication in the patient’s country. It is not intended to replace nutrition, physical activity or medical follow-up.
Semaglutide activates GLP-1 receptors involved in appetite and energy-intake regulation. It can increase satiety and reduce hunger and calorie intake. Response and tolerability differ between patients.
Wegovy is generally administered once weekly by subcutaneous injection. Follow the prescription and instructions supplied with the specific pen. Do not increase, reduce, combine or switch semaglutide strengths without medical guidance. Gradual dose escalation is used in part to improve gastrointestinal tolerability.
A clinician should review medical history, pregnancy status or plans, and concomitant medicines before treatment. Important risks and precautions can include gastrointestinal adverse effects, pancreatitis, gallbladder problems, dehydration-related kidney injury and hypoglycaemia when used with certain diabetes medicines. Seek medical attention for severe or persistent abdominal pain, serious allergic-reaction symptoms or other significant unexpected symptoms.
Frequently reported effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort, particularly while the dose is being increased. Persistent or severe symptoms, inability to maintain hydration or concerning symptoms should be assessed by a healthcare professional.
Cureiva lists the Wegovy dose pathway for product research: Wegovy 0.25 mg, Wegovy 0.5 mg, Wegovy 1 mg, Wegovy 1.7 mg, Wegovy 2.4 mg. These pages explain available strengths; they are not instructions to self-escalate treatment.
Patients researching treatment options can also read about liraglutide – Saxenda, tirzepatide 2.5 mg – Mounjaro KwikPen and orlistat 120 mg – Orligal. They differ in mechanism, dosing, indications and contraindications and are not interchangeable.
For independent evidence-based guidance, see NICE guidance on semaglutide for managing overweight and obesity and the current official prescribing information applicable to the patient’s country.
Wegovy is indicated for chronic weight management in eligible patients in jurisdictions where it is approved. Eligibility should be assessed by a healthcare professional.
Wegovy is generally injected once weekly. Follow the schedule provided with the prescribed product.
Patients should not choose a starting strength themselves. Wegovy uses a gradual dose-escalation schedule, and the appropriate stage depends on prior treatment and tolerability.
Response varies. Weight management is assessed over time, and early treatment includes dose escalation. Clinicians assess effectiveness, tolerability and whether treatment should continue.
Both contain semaglutide, but approved indications, dosing schedules and presentations differ by market. They should not be treated as automatically interchangeable.
Wegovy contains semaglutide; Mounjaro contains tirzepatide. They act through different incretin pathways and have different approved indications and dosing depending on jurisdiction.
Yes. Cureiva Healthcare accepts international enquiries, subject to prescription requirements, product availability, transport requirements and destination-country import rules.
Related educational guide: Wegovy, Ozempic and Rybelsus: differences and approved uses. Indications and available strengths vary by country; this guide does not replace prescribing information or clinical review.
Cureiva Healthcare provides product information and handles international enquiries subject to prescription requirements and destination-country regulations. This page is educational and does not replace diagnosis, prescribing advice, official product information or consultation with a qualified healthcare professional.
Last content review: October 2026